Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sutent in First Line for Papillary Renal Cell Carcinoma
NCT00541008Phase 2Completed
- Sponsor
- Unicancer
- Start
- Sep 2007
- Primary completion
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sunitinib in renal cell carcinoma (RCC), sponsored by Unicancer. Primary endpoint: Objective tumor response rate. Started Sep 2007; status: completed.
02
Drugs
sunitinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00541008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00541008.